Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gyre TherapeuticsGYRE +2.73%39 EV-to-EBITDA is 159.10 as of Aug. 06, 2026, which is 141% above its 10-year median of 65.91. GuruFocus rates GYRE with a GF Score™ of 39/100 and a GF Value™ of $9.76 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 409 Biotechnology companies, Gyre Therapeutics ranks worse than 95.35% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Gyre Therapeutics's enterprise value is $700.2 Mil.
Gyre Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $4.4 Mil. Therefore, Gyre Therapeutics's EV-to-EBITDA for today is 159.10.
The historical rank and industry rank for Gyre Therapeutics's EV-to-EBITDA or its related term are showing as below:
GYRE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 19.63 Med: 65.91 Max: 165.1
Current: 159.1
During the past 5 years, the highest EV-to-EBITDA of Gyre Therapeutics was 165.10. The lowest was 19.63. And the median was 65.91.
GYRE's EV-to-EBITDA is ranked worse than 95.35% of 409
companies
in the Biotechnology industry
Industry Median: 12.99
vs GYRE: 159.10
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gyre Therapeutics's PE Ratio (TTM) for today is calculated as:
Gyre Therapeutics's share price for today is $6.40.
Gyre Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.090.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Gyre Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Gyre Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's EV-to-EBITDA falls into.
Gyre Therapeutics's current Enterprise Value is $700.2 Mil.
Gyre Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gyre Therapeutics (GYRE) has a EV-to-EBITDA of 159.10 as of Aug. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Gyre Therapeutics. This is 141% above median its historical median of 65.91. Over the past decade, Gyre Therapeutics' EV-to-EBITDA has ranged from 19.63 to 165.10. According to the industry distribution chart, Gyre Therapeutics ranks #390 out of 409 companies in the Biotechnology industry, placing it in the top 95.4%.
Is Gyre Therapeutics' EV-to-EBITDA too high?
Gyre Therapeutics' current EV-to-EBITDA of 159.10 is 141% above median its 10-year median of 65.91. Over the past 10 years, this metric has ranged from a low of 19.63 to a high of 165.10. The Biotechnology industry median EV-to-EBITDA is 12.99. Gyre Therapeutics' value of 159.10 is 1124.8% above this industry median. Based on the distribution chart, Gyre Therapeutics ranks #390 out of 409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Gyre Therapeutics has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' EV-to-EBITDA compare to OCS and RIGL?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #390 out of 409 companies for EV-to-EBITDA. This places Gyre Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 12.99. Gyre Therapeutics' value of 159.10 is 1124.8% above this benchmark. Historically, Gyre Therapeutics' own EV-to-EBITDA has ranged from 19.63 to 165.10 over the past decade. While the company's 10-year median is 65.91 vs. the industry median of 12.99, Gyre Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.99, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gyre Therapeutics's current EV-to-EBITDA of 159.10 is 1124.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Gyre Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 12.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gyre Therapeutics's current EV-to-EBITDA is 159.10, which is 141% above median its own 10-year median of 65.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.76, compared to a current price of $6.40 — trading 34.4% below its estimated fair value. The current EV-to-EBITDA is 159.10, which is 141% above median its 10-year median of 65.91 and 1124.8% above the Biotechnology industry median of 12.99. Gyre Therapeutics' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current EV-to-EBITDA is 159.10 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gyre Therapeutics (GYRE) Overvalued in 2026?
Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued.
The current stock price of $6.40 is trading 34.4% below its estimated GF Value™ of $9.76.
GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.
Key valuation signals for GYRE:
EV-to-EBITDA: 159.10 (141% above median its 10-year median of 65.91)
GF Value™: $9.76 vs. price of $6.40 (34.4% below fair value)
Industry Position: 1124.8% above the Biotechnology median (#390 of 409)
No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score
Get the complete analysis for GYRE
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GYRE has been successfully added to your 
